HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Insights from the use of erythropoietin in experimental Chagas disease.

Abstract
In addition to the long-established role in erythropoiesis, erythropoietin (Epo) has protective functions in a variety of tissues, including the heart. This is the most affected organ in chronic Chagas disease, caused by the protozoan Trypanosoma cruzi. Despite seven million people being infected with T. cruzi worldwide, there is no effective treatment preventing the disease progression to the chronic phase when the pathological involvement of the heart is often observed. Chronic chagasic cardiomyopathy has a wide variety of manifestations, like left ventricular systolic dysfunction, dilated cardiomyopathy, and heart failure. Since Epo may help maintain cardiac function by reducing myocardial necrosis, inflammation, and fibrosis, this study aimed to evaluate whether the Epo has positive effects on experimental Chagas disease. For that, we assessed the earlier (acute phase) and also the later (chronic phase) use of Epo in infected C57BL/6 mice. Blood cell count, biochemical parameters, parasitic load, and echocardiography data were evaluated. In addition, histopathological analysis was carried out. Our data showed that Epo had no trypanocide effect nor did it modify the production of anti-T. cruzi antibodies. Epo-treated groups exhibited parasitic burden much lower in the heart compared to blood. No pattern of hematological changes was observed combining infection with treatment with Epo. Chronic Epo administration reduced CK-MB serum activity from d0 to d180, irrespectively of T. cruzi infection. Likewise, echocardiography and histological results indicate that Epo treatment is more effective in the chronic phase of experimental Chagas disease. Since treatment is one of the greatest challenges of Chagas disease, alternative therapies should be investigated, including Epo combined with benznidazole.
AuthorsAna Carolina de Castro Nobre, Carlos Fernando Pimentel, George Magno Sousa do Rêgo, Giane Regina Paludo, Glaucia Bueno Pereira Neto, Márcio Botelho de Castro, Nadjar Nitz, Mariana Hecht, Bruno Dallago, Luciana Hagström
JournalInternational journal for parasitology. Drugs and drug resistance (Int J Parasitol Drugs Drug Resist) Vol. 19 Pg. 65-80 (08 2022) ISSN: 2211-3207 [Electronic] Netherlands
PMID35772309 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Chemical References
  • Cardiovascular Agents
  • Erythropoietin
Topics
  • Animals
  • Cardiovascular Agents (therapeutic use)
  • Chagas Cardiomyopathy (drug therapy, parasitology)
  • Chagas Disease (drug therapy, parasitology)
  • Disease Models, Animal
  • Erythropoietin (therapeutic use)
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Parasite Load
  • Trypanosoma cruzi

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: